Business Wire

University Politehnica of Bucharest Opens First International NuScale Power Energy Exploration Center

Share

NuScale Power Corporation (NYSE: SMR) announced today the opening of a NuScale Energy Exploration Center (E2 Center) at University Politehnica of Bucharest in support of a collaboration with the United States and Romanian governments, and S.N. Nuclearelectrica S.A. (Nuclearelectrica). Key government officials attended the opening, including U.S. Ambassador to Romania Kathleen Kavalec, Romania Prime Minister Nicolae Ciuca, and Romanian Minister of Energy Virgil Popescu. As the first international E2 Center, this workforce development tool will enable Romania to develop the next generation of advanced nuclear experts, technologists, and operators and become a hub for deploying small modular reactors (SMR) in Europe.

“NuScale’s SMR nuclear technology is the premier global clean energy solution and can help advance Romania’s position as a leader in the secure and safe deployment of SMRs,” said John Hopkins, NuScale President and Chief Executive Officer. “With the support of the DOS under the FIRST program, we are thrilled to hit another milestone in this remarkable collaboration among our countries and organizations. We look forward to supporting the next generation of clean energy leaders across the region and around the globe.”

The E2 Center was funded by the U.S. Department of State (DOS) under the Foundational Infrastructure for the Responsible Use of Small Modular Reactor Technology (FIRST) program. FIRST supports partner countries in advancing their nuclear energy programs to meet their clean energy goals under the highest international standards for nuclear safety, security, and nonproliferation.

"The SMR project at Doicesti, which this E2 Center supports, will showcase Romanian leadership in energy innovation, accelerate the clean energy transition, create thousands of jobs in Romania and the U.S., and strengthen European energy security while upholding the highest standards for nuclear safety, security, and nonproliferation,” said Ann Ganzer, Principal Deputy Assistant Secretary, Bureau of International Security and Nonproliferation.

This announcement builds upon NuScale Power and Nuclearelectrica’s teaming agreement signed in 2021 to deploy a 462 MWe NuScale VOYGRTM-6 power plant in Romania by the end of the decade. Earlier this year, NuScale and RoPower Nuclear S.A. (RoPower), owned in equal shares by Nuclearelectrica and Nova Power & Gas S.A., commenced front-end engineering and design work for a site in Doicesti, Romania, the preferred location for the deployment of the VOYGR power plant.

Romania has the potential to be one of the first deployments of an SMR in Europe and to become a catalyst for SMRs in the region by serving as a base for supporting operations of this new technology in other countries, as well as the production and assembly of plant components.

“Building on the strong nuclear experience in safe operations for more than 26 years, we are proud to support Romania’s workforce development in the nuclear sector for a new technologically advanced future. Nuclearelectrica has outstanding specialists and operational performance, and is internationally recognized, which not only places Romanian nuclear industry as a top performer, but also as the foundation for Romania’s leadership in nuclear energy. Nuclearelectrica has strong assets, which qualifies us to be the first country after the U.S. to deploy a NuScale SMR. The first E2 Center launched in Romania is only the beginning of this new era in technology, human resources, safe, affordable clean energy, with multiple benefits for communities and industries, to which we are happy to contribute,” Cosmin Ghita, Chief Executive Officer of Nuclearelectrica.

“Nuclear energy and SMRs are included in Romania’s energy strategy as a main pillar for energy security and reaching our decarbonation targets. Our commitment to increase energy production from clean nuclear energy sources will create much needed complementarity with renewable resources, increase flexibility in the system, and allow further complex development of former coal-based facilities. The 26 years of Romanian safe operation expertise are the basis for further developing Romania’s nuclear energy program. The energy transition is not possible without maintaining and expanding the role of nuclear power and it requires strong international partnerships, like the one we are enhancing today. I thank our American partners for their continuous support, Nuclearelectrica for its leadership in the industry and capability to take on the journey to become a regional preferred operator, and University of Politehnica for their dedication towards performance and workforce development. I want to give a clear message: The Romanian Prime Minister Nicolae Ciuca, our Government, and Romanian President Klaus Iohannis strongly support the development of nuclear energy and the effort to form experts in this domain,” said Virgil Popescu, Minister of Energy, Romania.

The E2 Center is an innovative learning environment that offers users a hands-on opportunity to apply nuclear science and engineering principles through simulated, real-world nuclear power plant operation scenarios. The E2 Center employs state-of-the-art computer modeling to simulate a NuScale VOYGR SMR power plant control room. Users have the opportunity to take on the role of a “Control Room Operator” at a VOYGR plant to learn about the advanced operational and safety features unique to NuScale’s technology.

The University Politehnica of Bucharest is one of the elite schools of the Romanian higher education system. The school was established in 1950, and offers highly appreciated academic studies and programs for more than 2,000 students a year.

About NuScale Power

NuScale Power Corporation (NYSE: SMR) is the industry-leading provider of proprietary and innovative advanced small modular reactor nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. The company’s groundbreaking VOYGR™ SMR plants are powered by the NuScale Power Module™, a small, safe, pressurized water reactor that can each generate 77 megawatts of electricity (MWe) or 250 megawatts thermal (gross), and can be scaled to meet customer needs through an array of flexible configurations up to 924 MWe (12 modules) of output.

As the first and only SMR to have its design certified by the U.S. Nuclear Regulatory Commission, NuScale is well-positioned to serve diverse customers across the world by supplying nuclear energy for electrical generation, district heating, desalination, commercial-scale hydrogen production, and other process heat applications.

Founded in 2007, NuScale is headquartered in Portland, Ore. To learn more, visit NuScale Power’s website or follow us on Twitter , Facebook , LinkedIn , Instagram and YouTube .

Forward Looking Statements

This release may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. These forward-looking statements are inherently subject to risks, uncertainties and assumptions. Actual results may differ materially as a result of a number of factors. Caution must be exercised in relying on these and other forward-looking statements. Due to known and unknown risks, NuScale’s results may differ materially from its expectations and projections. NuScale specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NuScale’s assessments as of any date subsequent to the date of this release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Diane Hughes, Vice President, Marketing & Communications, NuScale Power
dhughes@nuscalepower.com
(503) 270-9329

Investor Contact
Scott Kozak, Director, Investor Relations, NuScale Power
skozak@nuscalepower.com
(541) 452-7583

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release

Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye